This manuscript provides a gene-chip examination of gastric ECL cell proliferation in an
animal model of neuroendocrine tumour disease. Data that were used to identify molecular …

In the past year, there have been major advances in our understanding of the mechanisms
of action of somatostatin. The cloning and characterizing of genes encoding five structurally …

Neuroendocrine tumors are rare neoplasms. During the last two decades, somatostatin
analogs, exerting their activity through both receptor binding and enzymatic inhibition …

Neuroendocrine tumours belong to a heterogeneous family of neoplasms, originating in
endocrine glands (such as the pituitary, parathyroid or the neuroendocrine adrenal glands) …

Neuroendocrine tumours (NETs) represent a heterogeneous family of neoplasms, which
may develop from different endocrine glands (such as the pituitary, the parathyroid or the …

Treatments for advanced neuroendocrine tumors were, until recently, rather limited. Salvage
surgery and liver‐directed therapy both have relatively limited impact, and systemic cytotoxic …

Patients with advanced neuroendocrine tumors may experience symptoms related to
tumoral secretion of hormones and vasoactive amines as well as symptoms related to tumor …

Neuroendocrine tumors are considered rare, although their incidence and prevalence have
significantly increased over the last two decades. 1 They are heterogeneous tumors in terms …

Neuroendocrine tumors (NETs) are epithelial neoplasms with neuroendocrine differentiation
that arise in various anatomic locations throughout the body. The annual incidence of NETs …

In recent decades, the incidence of neuroendocrine tumors (NETs) has steadily increased.
Due to the slow-growing nature of these tumors and the lack of early symptoms, most cases …